You are here: Industry Insights > HIV

News List

Those at risk of HIV to be offered PrEP drugs in England and Northern Ireland pharmafile
July 30, 2018
Those at risk of contracting HIV will now be offered PrEP drugs in England and Northern Ireland through a programme launched by the HIV and sexual health charity the Terrence Higgins Trust.
ViiV unveils positive data for two-drug HIV regimens pharmatimes
July 26, 2018
ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
US approves Janssen’s HIV pill Symtuza pharmatimes
July 19, 2018
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
EU nod for ViiV/Janssen's two-drug HIV regimen pharmatimes
July 13, 2018
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
EU nod for ViiV/Janssen's two-drug HIV regimen pharmatimes
July 12, 2018
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
Abivax drug lowers HIV DNA in blood and tissue, but has the opposite effect for some pharmafile
July 06, 2018
Biotechnology firm Abivax has lifted the curtain on new Phase 2a data for its HIV therapy ABX464, showing that the drug was able to reduce levels of the virus’ DNA in blood and rectal tissue.
Antiviral Treatments Reduce Cancer Risk for HIV Patients drugs
June 12, 2018
People with HIV are at increased risk for both AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma or invasive cervical cancer) and non-AIDS-related cancers (lung and larynx cancer, melanoma and leukemia).
Gilead, Hookipa pen hepatitis B, HIV research collaboration fiercebiotech
June 11, 2018
Gilead has licensed immunization technologies from Hookipa Biotech for use against hepatitis B and HIV. The big biotech is paying $10 million (€8.5 million) upfront and committing to milestones that could exceed $400 million to snag exclusive rights to tw
EU nod for ViiV/Janssen's two-drug HIV regimen pharmatimes
May 24, 2018
Juluca is comprised of ViiV’s dolutegravir, an integrase strand transfer inhibitor, and Janssen’s rilpivirine 25mg, a non-nucleoside reverse transcriptase inhibitor.
Institute of Human Virology (IHV) Will Undertake Largest HIV Survey Ever Conducted in a Single Country biospace
April 19, 2018
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine(UMSOM) will lead a $100 million project to measure the reach and impact of HIV programs in Nigeria

Previous page 1 2 3 4 5 6 7 8 9 10 ... 24 25 Next page